Amgen 2010 Annual Report Download - page 144

Download and view the complete annual report

Please find page 144 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

December 31, 2009, we recorded charges associated with these actions aggregating $70 million, primarily
comprised of staff separation costs of $25 million, principally included in “Other charges” in the Consolidated
Statement of Income, and integration related costs of $32 million, which were principally included in “Selling,
general and administrative” expenses in the Consolidated Statement of Income. During the year ended Decem-
ber 31, 2008, we recorded charges associated with these actions aggregating $148 million, primarily comprised of
loss accruals for certain leases that will not be used in our business of $59 million, asset impairment charges of
$59 million and staff separation costs of $10 million, all of which were primarily included in “Other charges” in the
Consolidated Statement of Income. The asset impairment charges principally represent the write-off of the total cost
of the manufacturing-related assets as they were abandoned with no alternative future uses or residual value.
9. Other charges
For the years ended December 31, 2010, 2009 and 2008, we recorded charges associated with cost savings
initiatives and/or restructuring totaling $118 million, $34 million and $92 million, respectively. Such expenses are
included in “Other charges” in the Consolidated Statements of Income. (See Note 8, Cost savings initiatives and
restructuring for further discussion.)
For the years ended December 31, 2009 and 2008, we recorded loss accruals for settlements of certain legal
proceedings aggregating $33 million and $288 million, respectively. The loss accruals for 2008 principally related
to the settlement of the Ortho Biotech Products L.P. antitrust suit. These amounts are included in “Other charges” in
the Consolidated Statements of Income.
10. Available-for-sale investments
The fair values of available-for-sale investments by type of security, contractual maturity and classification in
the Consolidated Balance Sheets were as follows as of December 31, 2010 and 2009 (in millions):
Type of security as of December 31, 2010
Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Estimated
fair value
U.S. Treasury securities ................................ $ 5,044 $ 50 $(14) $ 5,080
Other government related debt securities:
Obligations of U.S. government agencies and FDIC guaranteed
bank debt ....................................... 2,158 51 (1) 2,208
Foreign and other................................... 837 16 (1) 852
Corporate debt securities:
Financial ......................................... 2,252 53 (9) 2,296
Industrial ......................................... 2,441 71 (5) 2,507
Other............................................ 307 10 (1) 316
Mortgage and asset backed securities ...................... 841 5 (5) 841
Money market mutual funds ............................ 3,030 — — 3,030
Other short-term interest bearing securities .................. 147 — — 147
Total debt securities ............................... 17,057 256 (36) 17,277
Equity securities ..................................... 50 — (2) 48
$17,107 $256 $(38) $17,325
F-22
AMGEN INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)